Sign In
Buy DSNKY
$15.23
-0.94 (-5.81%)
At Close: Jun 03, 2026
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
07:00am, Wednesday, 03'rd Dec 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern Di
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:48pm, Monday, 01'st Dec 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
- The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity medicin
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. D
Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript
01:53am, Thursday, 06'th Nov 2025
Daiichi Sankyo Company, FQ2 2026 Earnings Call October 31, 2025 2:30 AM ET Company Participants Hiroyuki Okuzawa - President, CEO, Representative Director Joseph Kenneth Keller - President, CEO Ken Ta
Daiichi Sankyo Company, Limited (OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT Company Participants Ken
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations
Daiichi Sankyo Establishes Third Research Institute in San Diego
07:00am, Thursday, 02'nd Oct 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside o
Daiichi Sankyo Company, Limited (DSKYF) Q2 2024 Earnings Call Transcript
12:49pm, Wednesday, 01'st Oct 2025
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2024 Earnings Conference Call October 31, 2024 2:30 AM ET Company Participants Hiroyuki Okuzawa - Representative Director, President & Chief Operating
Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript)
12:35pm, Friday, 19'th Sep 2025
Daiichi Sankyo Company, Limited (OTCPK:DSNKY) Discusses on WCLC 2025 Highlights (Transcript) Company Participants Kentaro Asakura - Corporate Officer, Head of Corporate Communications Deptt, Global Co
MADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Immuto Scientific Announces Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfa
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different dose
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and diff
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 Worl
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
